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Background. HPV vaccination may prevent thousands of cases of cervical cancer. We aimed to evaluate the understanding and
acceptance of the HPV vaccine among adolescents. Methods. A questionnaire was distributed to adolescents at health clinics
aﬃliated with a large urban hospital system to determine knowledge pertaining to sexually transmitted diseases and acceptance
of the HPV vaccine. Results. 223 adolescents completed the survey. 28% were male, and 70% were female. The mean age for
respondents was 16 years old. Adolescents who had received the HPV vaccine were more likely to be female and to have heard of
cervical cancer and Pap testing. Of the 143 adolescents who had not yet been vaccinated, only 4% believed that they were at risk of
HPV infection and 52% were willing to be vaccinated. Conclusions. Surveyed adolescents demonstrated a marginal willingness to
receive the HPV vaccine and a lack of awareness of personal risk for acquiring HPV.
1.Introduction
Approximately 20 million people in the United States are
infected with genital human papillomavirus (HPV) [1]. An
estimated 5.5 million people will acquire a new genital HPV
infection each year, and the incidence of infection is highest
among sexually active adolescent girls and young women
between the age of 18 and 28 years old. It has been re-
ported that 37% of males and 28% of females in the ninth
grade have had sexual intercourse and 7% of students had
sexual intercourse before the age of 13 [2]. Therefore, HPV
vaccination ideally would be directed toward preadolescents
and young adolescents in an eﬀort to provide the greatest
public health beneﬁt oﬀered by a prophylactic HPV vaccine.
It is predicted that HPV vaccination will prevent thou-
sands of cases of cervical cancer worldwide. In addition,
the emotional stress and economic burden associated with
abnormal Papanicolaou test results and the treatment of
preinvasive cervical lesions will be greatly reduced. The
quadrivalent HPV vaccine (Gardasil, Merck & Co.) was
found to have 97% eﬃcacy at preventing HPV 16 and/or
18 related cervical intraepithelial neoplasia 2 or 3, adeno-
carcinoma in situ, and cervical cancer [3]. The quadrivalent
HPV is approved for use in males and females between 9
and 26 years of age. On October 16, 2009, the FDA ap-
proved a recombinant HPV bivalent vaccine (Cervarix,
GlaxoSmithKlineBiologicals)topreventcervicalcancerand
precancerous lesions caused by HPV types 16 and 18. This
HPV vaccine is approved for use in females between 10 and
25 years of age and is the second HPV vaccine licensed for
use in females in the United States.
Until recently, studies of women and young adults have
shown poor levels of knowledge about HPV, Papanicolaou
smear testing, and cervical cancer [4, 5]. Current research2 Journal of Oncology
indicatesthatunderstandinghasimproved.However,knowl-
edge of some relevant issues is higher than others. A review
by Brewer and Fazekas reported that only 21% of respon-
dents knew that HPV is common, 59% knew the purpose of
a Papanicolaou smear, and 68% knew that HPV is a sexually
transmitted infection [6]. In addition, awareness of HPV
among a racially diverse sample of young adults, aged 18–26
years old, was found to be relatively high, with more than
75% of study participants indicating that they had heard
of HPV from various sources [7]. However, another recent
study examining the acceptability of the HPV vaccination
among Latina immigrants and African American women
found that 61% of Latinas and 78% of African Americans
had never heard about HPV [8].
Continuing, several studies indicate that most parents,
especially with proper knowledge of HPV and the vaccine,
are willing to accept the HPV vaccine for their children
[9–12]. Healthcare providers are an important source of
information for parents and children, and studies show that
they generally have a positive attitude towards recommend-
ing HPV vaccination [13, 14]. The vaccination series can be
startedbeginningat9yearsold,andtheAdvisoryCommittee
on Immunization Practices currently recommends routine
vaccination of females aged 11 or 12 years with three doses
of HPV vaccine. In addition, the quadrivalent HPV vac-
cination has been approved in males aged 9 through 26
years to reduce their likelihood of acquiring genital warts.
Ideally, vaccination should be administered before potential
exposure to HPV through sexual contact [15].
The purpose of this study was to evaluate the under-
standing and potential acceptance of the HPV vaccine by
adolescents aged 13 to 18 years at adolescent health clinics
aﬃliated with New York Presbyterian Hospital. Although
previous research shows that most adolescents, parents, and
health care providers are willing to accept universal vaccina-
tion for themselves, their attitudes and knowledge regarding
the vaccine have yet to be evaluated. Improved knowledge
of adolescent understanding and acceptance of the HPV
vaccine would help practitioners provide appropriate and
useful information to parents, providers, and adolescents
when making the decision to vaccinate.
2.MaterialsandMethods
Approval for this study was received from the institutional
review board. We administered a questionnaire to all
adolescent patients (deﬁned as between 13 and 18 years
of age) awaiting annual well-patient medical examinations
in adolescent health clinics aﬃliated with Weill Cornell
Medical College and Columbia University Medical Center.
These health clinics provide aﬀordable, comprehensive ser-
vices to a diverse patient population including underserved
populations from each of the ﬁve boroughs in the New
York City area. The adolescent patient was provided the
questionnaire in English and/or Spanish. We could not
predict the number of adolescent patients who would be
interested in participating in this study, and therefore prior
to study initiation we deﬁned the survey collection period as
September 1, 2007 through February 1, 2008 with the goal
Table 1: Description of adolescent characteristics.
Variable n (%)






African American 47 (21.1)
















Jehovah’s Witness 3 (1.3)
No religion 29 (13.0)
Other 39 (17.5)
Blank 6 (2.7)
of collecting the maximum number of surveys possible. The
research personnel emphasized that participation was vol-
untary, anonymous, and without incentive for questionnaire
completion.
The questionnaire consisted of two parts; the ﬁrst
part elicited the adolescent’s demographic information and
knowledge pertaining to sexually transmitted diseases and
vaccinations. When the ﬁrst part was completed, the adoles-
cent was provided with a second part that contained current
facts about the HPV vaccine and cervical cancer, followed
by questions speciﬁcally designed to ascertain adolescent
acceptance of the vaccination. Adolescents whose primary
language was neither English nor Spanish were excluded
from the study since the questionnaire was self-administered
and available only in English and Spanish.
Data were analyzed using commercially available soft-
ware (SPSS version 16.0; SPSS, Inc., Chicago, IlL). A series
of χ2 and Fisher’s exact tests were used for comparison of
proportions between “HPV vaccine status” and 15 other
variables of interest (see Table 2) and “Willingness to receive
the HPV vaccine” and 15 other variables of interest (see
Table 3). A P value of < 0.05 was considered signiﬁcant for
all tests. For the series of 15 analyses, the sample sizes of 223
participants (HPV vaccinestatus) and 143 participants (will-
ingnesstobevaccinated)providedameanpower>99.9%for
detecting a diﬀerence between both whether the adolescentJournal of Oncology 3
Table 2: HPV vaccine status.
Have had HPV vaccine Have not had HPV vaccine Do not know P value
#% # % # %
Language 1.000
English 69 32.9% 137 65.2% 4 1.9%
Spanish 4 36.4% 7 63.6% 0 0.0%
Age (mean) 16.08 15.85 — 0.311
Gender <0.001
Male 2 3.1% 60 93.8% 2 3.1%
Female 71 45.2% 84 53.5% 2 1.3%
Race 0.677
African American 19 40.4% 27 57.4% 1 2.1%
Native American/Aleutian/Eskimo 0 0.0% 1 100.0% 0 0.0%
Hispanic 47 32.4% 95 65.5% 3 2.1%
Asian 0 0.0% 3 100.0% 0 0.0%
White 3 50.0% 3 50.0% 0 0.0%
Other 4 21.1% 15 78.9% 0 0.0%
Religion 0.708
Catholic 44 33.3% 86 65.2% 2 1.5%
Jewish 1 100.0% 0 0.0% 0 0.0%
Buddhist 0 0.0% 2 100.0% 0 0.0%
Protestant 0 0.0% 3 100.0% 0 0.0%
No Religion 11 37.9% 17 58.6% 1 3.4%
Muslim 2 25.0% 6 75.0% 0 0.0%
Jehovah’s Witness 0 0.0% 3 100.0% 0 0.0%
Other 15 38.5% 23 59.0% 1 2.6%
Blank 0 0.0% 4 100.0% 0 0.0%
Mother’s completed level of education 0.031
Less than high school 25 41.0% 36 59.0% 0 0.0%
High school/GED 19 22.9% 62 74.7% 2 2.4%
College 21 47.7% 23 52.3% 0 0.0%
Professional degree 4 22.2% 13 72.2% 1 5.6%
Other 1 16.7% 5 83.3% 0 0.0%
Blank 3 33.3% 5 55.6% 1 11.1%
Father’s completed level of education 0.287
<high school 25 37.9% 41 62.1% 0 0.0%
High school/GED 24 31.2% 50 64.9% 3 3.9%
College 7 26.9% 18 69.2% 1 3.8%
Professional degree 1 10.0% 9 90.0% 0 0.0%
Other 6 54.5% 5 45.5% 0 0.0%
Blank 10 32.3% 21 67.7% 0 0.0%
Has an older sibling who received the HPV vaccine 1
Yes 44 34.1% 83 64.3% 2 1.6%
No 27 34.6% 50 64.1% 1 1.3%
Blank 0 0.0% 1 1.0% 0 0.0%
Unclear 2 15.4% 10 76.9% 1 7.7%
Has a younger sibling who received the HPV vaccine 1
Yes 40 33.1% 79 65.3% 2 1.7%
No 29 34.1% 55 64.7% 1 1.2%
Blank 0 0.0% 1 100.0% 0 0.0%
Unclear 4 28.6% 9 64.3% 1 7.1%
Heard of cervical cancer <0.001
Yes 69 41.1% 97 57.7% 2 1.2%
No 4 7.5% 47 88.7% 2 3.8%4 Journal of Oncology
Table 2: Continued.
Have had HPV vaccine Have not had HPV vaccine Do not know P value
#% # % # %
Heard of Pap screening 0.003
Yes 44 42.7% 56 54.4% 3 2.9%
No 28 23.9% 88 75.2% 1 0.1%
Understand the goal of Pap screening 0.003
Yes 29 50.9% 27 47.4% 1 1.8%
No 43 26.7% 115 71.4% 3 1.9%
Heard of sexually transmitted disease 0.241
Yes 69 34.2% 130 64.4% 3 1.5%
No 4 21.1% 14 73.7% 1 5.3%
Have had other vaccines <0.001
Yes 35 72.9% 12 25.0% 1 2.1%
No 33 22.6% 112 76.7% 1 0.7%
Do not know 2 16.7% 8 66.7% 2 16.7%
Believe at risk for abnormal Pap/cervical cancer 0.333
Yes 8 57.1% 6 42.9% 0 0.0%
No 43 31.2% 92 66.7% 3 2.2%
Do not know 16 28.6% 39 69.6% 1 1.8%
had been vaccinated and whether the adolescent was willing
to receive the HPV vaccine and the respective variable, using
2-tailed test with statistical signiﬁcance deﬁned as P<0.05.
3. Results
Of the 223 adolescents who completed the survey, 28% were
male and 70% were female (2% did not respond to the
question). The mean age of respondents was 16 years old
(range13–18).Thedemographicsofadolescentsincludingin
this study are displayed in Table 1.Am a j o r i t yo fa d o l e s c e n t s
surveyed (168, 75%) stated that they had prior knowledge of
cervical cancer. However, a smaller percentage of adolescents
(103, 46%) acknowledged prior knowledge of what a “Pap
smear” was, and only 57 respondents (26%) were aware that
the Pap smear was used to screen for cervical cancer. 5%
(11)ofrespondentsreportedknowingsomeonewhohad/has
cervical cancer, and 91% (202) were familiar with the term
“sexually transmitted disease” or “STD”.
Of the 223 adolescent surveyed, 33% stated that they had
received the HPV vaccine, 64% had not had the vaccine, and
3% where not sure. Among the 143 adolescents who had
not yet been vaccinated, 52% were willing to get the HPV
vaccine, 12% were not willing, and 36% were unsure. Of the
143 adolescents who had not yet been vaccinated, only 4%
believed that they were at risk for being exposed to HPV.
Of the 73 respondents that stated that they had received
the HPV vaccine, the mean age was 16 years old (range 13–
18). Female respondents were more likely to have received
the HPV vaccine than male respondents (45% versus 3%,
P<0.001). HPV vaccination status was not signiﬁcantly
associated with language, race, religion, or having younger
or older siblings who had received the HPV vaccine. HPV
vaccine status was associated with knowledge of cervical
cancer (41% of those who had heard of cervical cancer
were vaccinated), knowledge of Pap screening (43% who had
heard of Pap screening were vaccinated), and having had
othervaccines(73%ofthosewhohadreceivedothervaccines
were vaccinated) (Table 2).
Among the adolescents who had not yet received the
HPV vaccine, 58% of females and 42% of males were willing
to be vaccinated; however this diﬀerence was not statistically
signiﬁcant. In addition, 53% of Hispanic adolescents and
56% of African American adolescents were willing to accept
vaccination. There was no association with willingness to
receive the vaccine and gender, race, religion, language,
having vaccinated siblings, knowledge of cervical cancer, Pap
screening, sexually transmitted disease, or any other studied
variable.
4. Discussion
The current study reveals only a marginal willingness of
teenagers to accept the HPV vaccine. The majority of data
to date suggest that young women are interested in vaccines
that prevent HPV and other sexually transmitted infections.
However, most of these studies have been conducted with
women and men of 18 years of age or older. Holcomb
et al. found that women are interested in learning about
HPV, how the virus is transmitted, and how women can
prevent becoming infected [16]. In 2001, a study of women
recruited from community and clinical sites displayed that
roughly 85% of participants indicated an intention to receive
an HPV vaccine for cervical cancer prevention once it
became available [17]. A study of young, Australian, men
and women aged 18–23 years old showed a high vaccine
acceptance despite inadequate knowledge of HPV infection
[18]. Another study of male and female college students
f o u n da no v e r a l la c c e p t a n c er a t eo ft h eH P Vv a c c i n eo f
74%. In this study, although females were more likely to
have already been vaccinated, gender did not aﬀect vaccine
acceptanceamongunvaccinatedadolescents[19].IncontrastJournal of Oncology 5
Table 3: Willingness to receive the HPV vaccine among adolescent who have not yet been vaccinated.
Yes No Do not know P
# % #%#%
Language 0.873
English 71 52.2% 17 12.5% 48 35.3%
Spanish 3 42.9% 1 14.3% 3 42.9%
Age (mean) 74 1605.00% 18 16.06 0.997
Gender 0.126
Male 25 42.4% 10 16.9% 24 40.7%
Female 49 58.3% 8 9.5% 27 32.1%
Race 0.062
African American 15 55.6% 0 0.0% 12 44.4%
Native American/Aleutian/Eskimo 0 0.0% 1 100.0% 0 0.0%
Hispanic 50 52.6% 13 13.7% 32 33.7%
Asian 0 0.0% 0 0.0% 2 100.0%
White 1 33.3% 1 33.3% 1 33.3%
Other 8 53.3% 3 20.0% 4 26.7%
Religion 0.569
Catholic 48 55.8% 10 11.6% 28 32.6%
Buddhist 0 0.0% 0 0.0% 1 100.0%
Protestant 1 33.3% 1 33.3% 1 33.3%
No Religion 10 58.8% 2 11.8% 5 29.4%
Muslim 1 16.7% 1 16.7% 4 66.7%
Jehovah’s Witness 1 33.3% 1 33.3% 1 33.3%
Other 11 47.8% 3 13.0% 9 39.1%
Blank 2 50.0% 0 0.0% 2 50.0%
Mother’s completed level of education 0.094
<high school 21 60.0% 3 8.6% 11 31.4%
High school/GED 35 56.5% 9 14.5% 18 29.0%
College 10 43.5% 2 8.7% 11 47.8%
Professional degree 7 53.8% 3 23.1% 3 23.1%
Other 0 0.0% 0 0.0% 5 100.0%
Blank 1 20.0% 1 20.0% 3 60.0%
Father’s completed level of education 0.204
<high school 25 62.5% 2 5.0% 13 32.5%
High school/GED 21 42.0% 8 16.0% 21 42.0%
College 6 33.3% 3 16.7% 9 50.0%
Professional degree 4 44.4% 3 33.3% 2 22.2%
Other 3 60.0% 0 0.0% 2 40.0%
Blank 15 71.4% 2 9.5% 4 19.0%
Has an older sibling who received the HPV vaccine 0.683
Yes 41 49.4% 13 15.7% 29 34.9%
No 26 52.0% 5 10.0% 19 38.0%
Blank 1 100.0% 0 0.0% 0 0.0%
Unclear 6 66.7% 0 0.0% 3 33.3%
Has a younger sibling who received the HPV vaccine 0.183
Yes 41 51.9% 7 8.9% 31 39.2%
No 26 47.3% 11 20.0% 18 32.7%
Blank 1 100.0% 0 0.0% 0 0.0%
Unclear 6 75.0% 0 0.0% 2 25.0%
Heard of cervical cancer 0.111
Yes 55 56.7% 13 13.4% 29 29.9%
No 19 41.3% 5 10.9% 22 47.8%6 Journal of Oncology
Table 3: Continued.
Yes No Do not know P
#%#%#%
Heard of Pap screening 0.131
Yes 33 58.9% 6 10.7% 17 30.4%
No 41 47.1% 12 13.8% 34 39.1%
Know the use of Pap 0.451
Yes 16 59.3% 4 14.8% 7 25.9%
No 56 49.1% 14 12.3% 44 38.6%
Heard of sexually transmitted disease 0.447
Yes 69 53.5% 16 12.4% 44 34.1%
No 5 35.7% 2 14.3% 7 50.0%
Have had other vaccines 0.319
Yes 9 75.0% 1 8.3% 2 16.7%
No 53 47.7% 17 15.3% 41 36.9%
Do not know 6 50.0% 0 0.0% 6 50.0%
Believe at risk for abnormal Pap/cervical cancer 0.3
Yes 3 50.0% 2 33.3% 1 16.7%
No 46 50.0% 13 14.1% 33 35.9%
Do not know 21 55.3% 2 5.3% 15 39.5%
to most of the data available in the literature, this current
review sampled a younger population. We found a general-
ized lack of awareness of HPV among adolescents. Although
the majority of adolescents had heard of cervical cancer
(75%), only 46% knew what a Pap smear was, and only 26%
knewthatthePapsmearisascreeningtestforcervicalcancer.
Furthermore, only 4% of the adolescents surveyed who had
not yet received the HPV vaccine believed that they were at
risk for HPV infection. The lack of awareness about cervical
cancer screening and underestimated risk of HPV risk likely
contributes to the limited willingness of the adolescents
surveyed to accept the HPV vaccine for themselves.
Many of the adolescents stated that they would seek
advice from a parent or physician when deciding whether or
not to accept the HPV vaccine. Interestingly, we found no
signiﬁcant association between having had the HPV vaccine
or willingness to receive the vaccine and the level of educa-
tionoftheadolescent’sparents.Therewasalsonoassociation
between having younger or older siblings who had been
vaccinated and having had the HPV vaccine or willingness
to receive the vaccine. Many studies have shown that most
parents are willing to accept the HPV vaccine for their chil-
dren. A recent study, postlicensure of the vaccine, evaluated
mothers of children in primary and secondary schools in
England and found that 75% of mothers would accept
the HPV vaccine for their daughter. Acceptance was higher
in mothers who had experienced cancer in their families,
had older daughters, perceived approval from their hus-
bands/partners, and believed vaccine acceptance would be
more normative [20]. Another postlicensure study used a
random-digit-dial telephone survey to examine the likeli-
hood of parental acceptance of the HPV vaccination for
youngadolescentgirlsinCalifornia.Withinthissample,75%
of parents were likely to vaccinate a daughter before age 13.
Hispanic parents were more likely to accept vaccination than
werenon-Hispanicparents,andAfricanAmericanandAsian
American parents were the least likely to accept vaccination
[21]. Overall, parental attitude and acceptance studies sug-
gest a great deal of parental interest in HPV vaccination
for their adolescent children. Healthcare providers may be
able to encourage participation in HPV vaccine programs
by bolstering parents’ underlying desire to protect their
children, as recommendation by a healthcare provider is a
crucial prompt for vaccination.
Healthcare providers are an important source of infor-
mation for parents and children, and studies show that they
generally have a positive attitude towards recommending an
HPV vaccination. One study of 207 fellows of the Amer-
ican College of Obstetricians and Gynecologists found a
fairly positive disposition towards recommending the HPV
vaccine, with a mean rating for vaccine recommendation of
79 out of 100 [22]. Similarly, 224 nurse practitioners had a
favorableattitudeaboutHPVvaccinerecommendation,with
a mean rating of 72 out of 100 [23]. Our study reveals that
knowledge of cervical cancer and Pap screening is associated
with having had the HPV vaccine, however interestingly not
with willingness to accept the vaccine among those not yet
vaccinated.
Previous studies have shown that knowledge of personal
risk is generally limited with regard to sexually transmitted
infections. A study of sexually active heterosexual college
students found that personal risk of contracting Acquires
Immune Deﬁciency Syndrome was estimated to be signiﬁ-
cantlylowerthanriskforeachofasetofhypotheticalpersons
who varied in degree of similarity to respondents [24].
In a study of university students in the United Kingdom,
screening for chlamydia was limited, and perception of per-
sonal risk was poor [25]. In a pilot study among Australian
university students, even though the majority of students
were comfortable with opportunistic testing for chlamydia
by their general practitioner, the likelihood of being tested
in the upcoming year for most students was low, as wasJournal of Oncology 7
personal concern about chlamydia infection [26]. With re-
gard to HPV, a recent study of Australian women with di-
verse sexual orientation, found that the majority of women
had risk factors for HPV but few felt personally at risk of
acquiring infection [27]. Among the 143 adolescents in our
study who had not yet received the HPV vaccine, only 4%
believed that they were at risk for being exposed to HPV.
The very low personal risk perception for HPV suggests the
need for targeted education for this group regarding HPV
transmission and prevention.
Study limitations should be considered when interpret-
ing the present ﬁndings. Participants were recruited from a
hospital-based adolescent health clinic serving a racially and
ethnically diverse, predominantly low-income, population.
As a result, the ﬁndings may not be applicable to all ad-
olescents in the United States. In order to include 13 and
14 years old in this study at an adolescent health clinic, we
were unable to ask certain direct questions, including “Are
you sexually active?”. The answer to this question may have
provided more information regarding age of sexual activity
in the current study population and would allow direct
comparison of these results with a personal risk perception
question. In addition, because the time frame was not stated
explicitly in the question regarding personal risk, it is unclear
whether participants were rating their risk of HPV infection
at present, in the immediate future, or over their lifetime,
which would also aﬀect the accuracy of their ratings.
5. Conclusion
It is clear that education will play an important role in
the implementation of an HPV vaccination program. In
this study, only 53% of adolescents who had not yet re-
ceived the HPV vaccine were willing to be vaccinated, and
lack of education likely contributes to this hesitancy. Health-
care providers must be proactive in educating and discussing
beneﬁts of vaccination. Based on factors aﬀecting vaccine
acceptability, HPV vaccine programs in the United States
should emphasize high vaccine eﬀectiveness, the high like-
lihood of HPV infection, physician recommendations, and
address barriers to vaccination. It is important to educate
patients that the vaccine is most eﬀe c t i v ep r i o rt os e x u a l
activity and HPV exposure. However, the vaccine does not
replace routine screening for cervical cancer or the need
for education about continued cervical cancer screening.
Thus, it is essential for healthcare providers to oﬀer guidance
about the ongoing need for screening. Future studies will
be necessary to evaluate public health issues that arise once
the HPV vaccination programs have been established more
extensively.
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